Credit Suisse’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $23.3M | Sell |
169,161
-31,020
| -15% | -$4.24M | 0.02% | 590 |
|
|
2023
Q4 | $26.4M | Sell |
200,181
-32,664
| -14% | -$3.76M | 0.03% | 582 |
|
|
2023
Q3 | $26.2M | Sell |
232,845
-7,639
| -3% | -$804K | 0.03% | 572 |
|
|
2023
Q2 | $22.7M | Sell |
240,484
-24,944
| -9% | -$2.44M | 0.02% | 629 |
|
|
2023
Q1 | $26.9M | Buy |
265,428
+58,512
| +28% | +$6.09M | 0.03% | 585 |
|
|
2022
Q4 | $24.7M | Sell |
206,916
-104
| -0.1% | -$12.2K | 0.03% | 605 |
|
|
2022
Q3 | $22M | Buy |
207,020
+39,561
| +24% | +$4.01M | 0.02% | 631 |
|
|
2022
Q2 | $16.3M | Sell |
167,459
-3,109
| -2% | -$287K | 0.02% | 755 |
|
|
2022
Q1 | $16M | Sell |
170,568
-10,433
| -6% | -$884K | 0.01% | 852 |
|
|
2021
Q4 | $15.4M | Buy |
181,001
+41,585
| +30% | +$3.83M | 0.01% | 1223 |
|
|
2021
Q3 | $13.4M | Buy |
139,416
+12,715
| +10% | +$1.2M | 0.01% | 1340 |
|
|
2021
Q2 | $12.3M | Buy |
126,701
+17,305
| +16% | +$1.66M | 0.01% | 1423 |
|
|
2021
Q1 | $10.6M | Buy |
109,396
+907
| +0.8% | +$95.1K | 0.01% | 1550 |
|
|
2020
Q4 | $10.4M | Sell |
108,489
-640
| -0.6% | -$61.8K | 0.01% | 1549 |
|
|
2020
Q3 | $10.5M | Buy |
109,129
+1,281
| +1% | +$148K | 0.01% | 1353 |
|
|
2020
Q2 | $13.2M | Buy |
107,848
+3,972
| +4% | +$439K | 0.01% | 1156 |
|
|
2020
Q1 | $8.99M | Sell |
103,876
-34,961
| -25% | -$3.42M | 0.01% | 1229 |
|
|
2019
Q4 | $14.9M | Buy |
138,837
+19,747
| +17% | +$2.07M | 0.01% | 1191 |
|
|
2019
Q3 | $10.7M | Buy |
119,090
+45,344
| +61% | +$4.24M | 0.01% | 1262 |
|
|
2019
Q2 | $6.23M | Sell |
73,746
-1,798
| -2% | -$148K | 0.01% | 1601 |
|
|
2019
Q1 | $6.66M | Sell |
75,544
-340,815
| -82% | -$28.5M | 0.01% | 1503 |
|
|
2018
Q4 | $29.7M | Buy |
416,359
+100,569
| +32% | +$9.64M | 0.03% | 583 |
|
|
2018
Q3 | $38.8M | Buy |
315,790
+29,742
| +10% | +$3.37M | 0.03% | 525 |
|
|
2018
Q2 | $28.1M | Sell |
286,048
-171,321
| -37% | -$15.3M | 0.03% | 654 |
|
|
2018
Q1 | $37.9M | Buy |
457,369
+130,933
| +40% | +$11.1M | 0.04% | 536 |
|
|
2017
Q4 | $25.3M | Buy |
326,436
+89,320
| +38% | +$6.09M | 0.02% | 764 |
|
|
2017
Q3 | $14.5M | Sell |
237,116
-20,030
| -8% | -$1.06M | 0.01% | 1027 |
|
|
2017
Q2 | $11.8M | Sell |
257,146
-71,199
| -22% | -$3.45M | 0.01% | 1106 |
|
|
2017
Q1 | $14.2M | Buy |
328,345
+90,741
| +38% | +$3.89M | 0.01% | 1023 |
|
|
2016
Q4 | $9.2M | Sell |
237,604
-13,021
| -5% | -$589K | 0.01% | 1261 |
|
|
2016
Q3 | $12.7M | Sell |
250,625
-69,781
| -22% | -$3.48M | 0.01% | 1053 |
|
|
2016
Q2 | $14.6M | Buy |
320,406
+19,047
| +6% | +$877K | 0.02% | 939 |
|
|
2016
Q1 | $11.9M | Buy |
301,359
+27,931
| +10% | +$1.11M | 0.01% | 1012 |
|
|
2015
Q4 | $15.5M | Buy |
273,428
+22,678
| +9% | +$1.15M | 0.02% | 919 |
|
|
2015
Q3 | $9.98M | Sell |
250,750
-80,779
| -24% | -$3.9M | 0.01% | 1117 |
|
|
2015
Q2 | $15.8M | Buy |
331,529
+43,750
| +15% | +$1.86M | 0.02% | 957 |
|
|
2015
Q1 | $11.4M | Buy |
287,779
+34,566
| +14% | +$1.24M | 0.01% | 1121 |
|
|
2014
Q4 | $5.66M | Buy |
253,213
+25,284
| +11% | +$479K | 0.01% | 1672 |
|
|
2014
Q3 | $3.57M | Buy |
227,929
+51,008
| +29% | +$762K | ﹤0.01% | 2019 |
|
|
2014
Q2 | $2.63M | Sell |
176,921
-61,707
| -26% | -$871K | ﹤0.01% | 2485 |
|
|
2014
Q1 | $3.84M | Buy |
238,628
+24,603
| +11% | +$421K | ﹤0.01% | 1979 |
|
|
2013
Q4 | $2M | Sell |
214,025
-72,203
| -25% | -$705K | ﹤0.01% | 2642 |
|
|
2013
Q3 | $3.24M | Buy |
286,228
+143,988
| +101% | +$1.98M | ﹤0.01% | 1984 |
|
|
2013
Q2 | $1.9M | Buy |
+142,240
| New | +$1.75M | ﹤0.01% | 2311 |
|
Other funds holding NBIX
BG
Credit Suisse's NBIX Position: Q1 2024 in Review
Credit Suisse reduced its Neurocrine Biosciences (NBIX) stake by 15% in Q1 2024, selling an estimated $4.24M and leaving 169,161 shares worth $23.3M. The position accounts for 0.02% of the portfolio, ranked #590.
Credit Suisse first reported a position in NBIX in Q2 2013 and has held it in 44 quarters since. The position peaked at $38.8M in Q3 2018. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.
- Credit Suisse held 169,161 shares of Neurocrine Biosciences worth $23.3M as of Q1 2024.
- Credit Suisse sold 31,020 Neurocrine Biosciences shares in Q1 2024, an estimated $4.24M.
- Neurocrine Biosciences made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #590 holding.
- Credit Suisse first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Neurocrine Biosciences position peaked at $38.8M in Q3 2018.
- 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.